Stay up to date with the latest news and developments from the pharmaceutical, biotechnology, and life sciences industries. Our editorial team closely monitors global industry trends, breakthroughs, regulatory updates, business activities, and innovations to bring you timely, accurate, and insightful news from around the world
J&J announces Phase 3 LIBREXIA-STROKE trial results evaluating milvexian, an oral factor XIa inhibitor, for secondary stroke prevention.
Roche announces positive Phase 3 ALINA trial results showing Alecensa (alectinib) significantly improves disease-free survival in resected ALK-positive NSCLC.
AbbVie announces Phase 2 trial results showing navitoclax plus ruxolitinib achieves hematologic responses in patients with polycythemia vera resistant or intolerant to hydroxyurea.
Merck presents five-year overall survival data from KEYNOTE-177 trial showing sustained benefit of Keytruda as first-line treatment for MSI-H/dMMR colorectal cancer.
Pfizer announces Phase 3 ALLEGRO trial results showing ritlecitinib significantly promotes hair regrowth in adults and adolescents with alopecia areata.
AstraZeneca announces Phase 3 trial results showing roxadustat effectively treats anemia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies.
Novartis announces Phase 3 APPEAR-C3G trial results showing iptacopan significantly reduces proteinuria and improves kidney function in C3 glomerulopathy.
Gilead Sciences presents overall survival data from ASCENT trial showing Trodelvy (sacituzumab govitecan) provides significant survival benefit in metastatic TNBC.
Regeneron and Sanofi share two-year follow-up data from BOREAS trial showing sustained reduction in COPD exacerbations with itepekimab in former smokers.
Sanofi announces Phase 3 PEGASUS trial results showing rilzabrutinib significantly reduces disease activity in patients with moderate-to-severe pemphigus vulgaris.
